IL290509A - Antibodies that bind to lrp5 proteins and methods of use - Google Patents

Antibodies that bind to lrp5 proteins and methods of use

Info

Publication number
IL290509A
IL290509A IL290509A IL29050922A IL290509A IL 290509 A IL290509 A IL 290509A IL 290509 A IL290509 A IL 290509A IL 29050922 A IL29050922 A IL 29050922A IL 290509 A IL290509 A IL 290509A
Authority
IL
Israel
Prior art keywords
antibodies
bind
methods
lrp5 proteins
lrp5
Prior art date
Application number
IL290509A
Other languages
English (en)
Hebrew (he)
Original Assignee
Modmab Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modmab Therapeutics Inc filed Critical Modmab Therapeutics Inc
Publication of IL290509A publication Critical patent/IL290509A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL290509A 2019-08-14 2022-02-10 Antibodies that bind to lrp5 proteins and methods of use IL290509A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962886913P 2019-08-14 2019-08-14
PCT/CA2020/051119 WO2021026665A1 (en) 2019-08-14 2020-08-14 Antibodies that bind to lrp5 proteins and methods of use

Publications (1)

Publication Number Publication Date
IL290509A true IL290509A (en) 2022-04-01

Family

ID=74570326

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290509A IL290509A (en) 2019-08-14 2022-02-10 Antibodies that bind to lrp5 proteins and methods of use

Country Status (10)

Country Link
US (1) US20230183336A1 (https=)
EP (1) EP4013791A4 (https=)
JP (1) JP7840842B2 (https=)
KR (1) KR20220078568A (https=)
CN (2) CN119798435A (https=)
AU (1) AU2020329092A1 (https=)
CA (1) CA3147827A1 (https=)
IL (1) IL290509A (https=)
MX (1) MX2022001947A (https=)
WO (1) WO2021026665A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4547713A2 (en) * 2022-06-30 2025-05-07 The University of Chicago Cd73 (nt5e) targeting polypeptides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
US9200072B2 (en) * 2012-01-18 2015-12-01 Genentech Inc. Anti-LRP5 antibodies and methods of use
US20190194314A1 (en) * 2012-12-21 2019-06-27 Stowers Institute For Medical Research Antibodies for modulating binding between lrp and wise
US10294294B2 (en) * 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
UA122079C2 (uk) * 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
CA3077518C (en) * 2016-09-07 2021-10-19 Frederic Fellouse Synthetic antibodies against vegf and their uses
EP3630816B1 (en) * 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
EP3700930A1 (en) * 2017-10-25 2020-09-02 The Regents of the University of California Antibodies against cdcp1 for the treatment and detection of cancer
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7550647B2 (ja) * 2018-02-14 2024-09-20 アントレラ セラピューティクス インコーポレイテッド Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用
US10640562B2 (en) * 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
CA3111087A1 (en) * 2018-08-29 2020-03-05 Nanjing Legend Biotech Co., Ltd. Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof

Also Published As

Publication number Publication date
US20230183336A1 (en) 2023-06-15
CN114599679A (zh) 2022-06-07
CN119798435A (zh) 2025-04-11
EP4013791A1 (en) 2022-06-22
WO2021026665A1 (en) 2021-02-18
CN114599679B (zh) 2024-10-18
EP4013791A4 (en) 2024-01-24
JP7840842B2 (ja) 2026-04-06
CA3147827A1 (en) 2021-02-18
KR20220078568A (ko) 2022-06-10
MX2022001947A (es) 2022-06-14
AU2020329092A1 (en) 2022-03-31
JP2022544308A (ja) 2022-10-17

Similar Documents

Publication Publication Date Title
IL281683A (en) Dll3 binding proteins and methods of use
IL281783A (en) Sirpα binding proteins and methods of use thereof
IL269074A (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL270814A (en) Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
IL271231A (en) Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
IL271009A (en) Antibodies that specifically bind pd-1 and methods of use
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
PL3606955T3 (pl) Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
PL3484916T3 (pl) Przeciwciała swoiste wobec hiperfosforylowanego białka tau i sposoby ich zastosowania
HRP20260195T1 (hr) Proteini koji vežu anti-tl1a antigen i njihova upotreba
LT3618928T (lt) Anti-sortilino antikūnai ir jų panaudojimo būdai
HUE065544T2 (hu) Emberi anti-rankl ellenanyagok készítményei és eljárások alkalmazásukra
IL290509A (en) Antibodies that bind to lrp5 proteins and methods of use
IL287039A (en) Cd19 antibodies and methods of using the same
PL3565828T3 (pl) Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania
IL286641A (en) Engineered iga antibodies and methods of use
IL283136A (en) Antibodies to mucin-16 and methods of use thereof
IL284367A (en) Monoclonal antibodies that bind specifically to human trbv9
IL290233A (en) Antigen-binding protein constructs and uses thereof
EP3887389A4 (en) Polypeptides and methods for improving skin conditions
IL282193A (en) Nk engager molecules and methods of use thereof
IL270772A (en) Antibody-cytokine engrafted proteins and methods of use for immune related disorders
IL287385A (en) Use of an anti-cd19 antibody to treat autoimmune disease